Your browser does not support JavaScript or it may be disabled!
 India As It Happens
Rediff Labs will showcase innovative products that rediff is working on behind the scenes.
News   |   Images
Get Realtime News
on your webpage

About 118 results for "biocon under kiran mazumdar shaw"

Mylan-Biocon''s Biosimilar Cancer Drug Comparable To Roche''s Herceptin: Study

Biocon, Quark Announce Initiation of Pivotal Phase II/III Stud...

Biocon Chairperson & Managing Director Kiran Mazumdar-Shaw said: Biocon is committed to develop innovative therapies that address unmet medical needs and the initiation of the Phase II/III study investigating QPI-1007 in NAION in India is an ... BizWire Express, 1 month ago
Biocon's Insulin Glargine Launched in Japan Businessworld India, 1 week ago
Biocons Insulin Glargine Launched in Japan Pharma Focus Asia, 1 week ago

54 images for biocon under kiran mazumdar shaw

The Hindu, 1 day ago, 2 days ago
Oneindia, 1 day ago
Deccan Chronicle, 4 weeks ago
Hindu Business Line, 1 month ago, 1 month ago
Indiatimes, 1 month ago
Business Standard, 1 month ago, 1 month ago
Business Standard India, 1 month ago
Business Standard India

Mylan, Biocon report efficacy of cancer drug

Kiran Mazumdar Shaw Global pharma major Mylan Inc., and Biocon have confirmed the efficacy and safety of MYL-1401O, a proposed biosimilar trastuzumab co-developed by the firms, in comparison to Roche's branded Herceptin used for treatment of ...
 The Hindu1 month ago Mylan, Biocon upbeat on trial data involving breast cancer drug  Hindu Business Line1 month ago Pharma cos have increased focus on quality controls: Biocon CMD  Moneycontrol.com1 week ago Mylan, Biocon confirm efficacy of trastuzumab biosimilar  New Indian Express1 month ago

Biocon-Mylan to file 4 drug applications in FY17 under rev-share

The company is going to submit data to US FDA and European authorities for approval in a few months time, says Kiran Mazumdar Shaw, CMD, Biocon.
 Money Control1 month ago
Financial Express

Biocon April-June net profit up 17% to Rs 147 crore

Aided by a robust growth in biologics and branded formulations segments, bio-pharma major Biocon has reported a 17% year-on-year net profit growth at R147 crore for the first quarter ended June 30, 2016. During the corresponding quarter last year, ...
 Financial Express1 day ago Biocon net up 17 percent in Q1  IndUS Business Journal1 day ago Biocon net up 17% in Q1  ProKerala.com1 day ago

Stocks in focus: Raymond, Biocon, ITC, Bharat Financial Inclusion

Shares of diversified group Raymond today tanked 5.5 per cent after the company reported widening of consolidated net loss to Rs 16.61 crore for the quarter ended June 30, 2016. The stock slumped 5.51 per cent to Rs 463 on the BSE. On the NSE, ...
 Hindu Business Line1 day ago

Karnataka to see more global investments as govt permits 74% FDI under automatic route for Brownfield projects

Karnataka which has been a hub for global pharma production directly and through contract manufacturing route is now upbeat on the Union government consenting 74 per cent Foreign Direct Investment (FDI) under the automatic route in Brownfield ...
 PharmaBiz1 month ago FDI up to 74% in brownfield pharma under automatic route [Seven Days (United Arab Emirates)]  Pharmacy Choice1 month ago FDI norms relaxation a long-awaited reform: Shaw  Equilibrio Informativo1 month ago Pharma sector: green shoots for brownfield projects  Hindu Business Line1 month ago

Indian Pharma Is Committed to the Future, Says Biocon Managing Director

Investment in talent and infrastructure, more quality-by-design skills, and increased communication with global regulators will be needed to combat compliance issues at API and drug manufacturing facilities in India. Recently, there have been ...
 PharmTech.com1 month ago
International Business Times India

Biocon to develop oral insulin on its own after US drugmaker opts out of joint project

NotwithstandingU.S.-based pharma firm Bristol Myers Squibb (BMS) opting out of the joint project, Bengaluru-based biopharma company Biocon said on Tuesday that it would go ahead with the development of its oral insulin drug. A Biocon spokesperson ...
 International Business Times India2 months ago

Mallya keen on returning to India; makes new settlement offer to SBI

Three weeks after Mumbai Mirror reported that Vijay Mallya's private jet underwent amakeover supervised by the Air India's engineers before its auction this month, it has now emerged that the plane's auction has been postponed to June 29-30 as only ...
 Equilibrio Informativo2 months ago Vijay Mallya tells UB board he has every intention of repaying loans  Livemint.com2 months ago United Breweries board seeks legal view on Sebi's wilful defaulter rules  Economic Times2 weeks ago Have every intention of repaying loans: Mallya reassures UB board  Hindustan Times2 months ago

Biocon, Quark get DCGI nod for trials of new eye disease drug

Smith & Wesson Extreme Ops Pocket Knife for $10 + free shipping Animooos Puppy Training Pads 10-Pack for $8 + free shipping Samsung 128GB USB 3.0 Flash Drive for $29 + free shipping Amid campaign worries, Trump to check on courses in Scotland ...
 NewsFlow241 month ago
Prev | Next
Personalize your Realtimeclose [x]
Add content to your personalized tab - My News
Add upto 6 topics of your interest:
for eg.2g Scam , World
Personalize the tabs display. ( You can add or remove the tabs )
AlertsGet updates on latest news & your favourite topics right in your inbox.Set an Alert|Manage your Alerts


Realtime News

on your Webpage

Add Widget >Get your members hooked!
Related Queries - biocon under kiran mazumdar shaw
Get updated on latest news & your favorite topics right in your inbox!
More     Less